AngioDynamics (NASDAQ:ANGO) Announces Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07, RTT News reports. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share. The business’s revenue for the quarter was down .1% on a year-over-year basis. AngioDynamics updated its FY 2025 guidance to -0.380–0.340 EPS and its FY25 guidance to ($0.38)-($0.34) EPS.

AngioDynamics Trading Up 37.7 %

ANGO opened at $12.94 on Thursday. The company’s 50 day moving average is $7.99 and its 200 day moving average is $7.34. The company has a market cap of $525.80 million, a price-to-earnings ratio of -2.12 and a beta of 0.59. AngioDynamics has a 12-month low of $5.26 and a 12-month high of $13.13.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ANGO shares. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of AngioDynamics in a research note on Tuesday, December 10th. Canaccord Genuity Group lowered their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, October 4th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.